Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 3:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 919 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer, Node-positive Breast Cancer, Breast Adenocarcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ
Interventions
External Beam Radiation Therapy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
2
States / cities
Richmond, Virginia • South Hill, Virginia
Conditions
Breast Cancer
Interventions
IMRT/VMAT-Based Accelerated Partial Breast Irradiation
Radiation
Lead sponsor
Sanford Health
Other
Eligibility
50 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Worthington, Minnesota • Sioux Falls, South Dakota
Conditions
Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis and Ureter Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis and Ureter Cancer AJCC v7, Stage III Ureter Cancer AJCC v7
Interventions
Biospecimen Collection, Clinical Observation, Computed Tomography, CT Urography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
913
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 571 more
Conditions
Breast Cancer
Interventions
Tamoxifen, Anastrozole, Fulvestrant
Drug
Lead sponsor
Priscilla McAuliffe
Other
Eligibility
Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
Conditions
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions
Nadofaragene Firadenovec, Gemcitabine, Docetaxel, Pembrolizumab
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
40
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
EnteroTracker
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
Interventions
Investigational Imaging device, AVB-620
Device · Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Biopsy, Conventional Surgery, Genetic Testing
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Urothelial Carcinoma of the Urinary Bladder
Interventions
VAX014
Drug
Lead sponsor
Vaxiion Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Denver, Colorado • Iowa City, Iowa • Edison, New Jersey + 2 more
Conditions
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions
Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
424
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 293 more
Conditions
Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma, Fatigue Related to Cancer Treatment
Interventions
Naltrexone, Sugar Pill
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Superficial Bladder Cancer
Interventions
Whole bladder laser light treatment as an alternative to radical cystectomy, Photofrin
Procedure · Drug
Lead sponsor
North Florida/South Georgia Veterans Health System
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Malignant Neoplasm, Leukemia, Lymphoma, Malignant Solid Neoplasm, Sarcoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Thyroid Gland Carcinoma
Interventions
Internet Mobile Technology, Internet-Based Intervention, Questionnaire Administration, Supportive Care, Informational Intervention
Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more
Conditions
Acute Myeloid Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Childhood Acute Monoblastic Leukemia, Childhood Acute Monocytic Leukemia, Childhood Acute Myeloid Leukemia in Remission, Childhood Acute Myeloid Leukemia With Maturation, Childhood Acute Myeloid Leukemia With Minimal Differentiation, Childhood Acute Myeloid Leukemia Without Maturation, Childhood Acute Myelomonocytic Leukemia, Fungal Infection, Myeloid Neoplasm, Neutropenia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Myeloid Neoplasm
Interventions
Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Months to 30 Years
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
166
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 125 more
Conditions
Non Muscle Invasive Bladder Cancer
Interventions
N803 plus Bacillus Calmette-Guerin (BCG)
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102, TURBT
Drug · Procedure
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
33
States / cities
Tucson, Arizona • Loma Linda, California • Los Angeles, California + 30 more
Conditions
Barrett Esophagus, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia, Esophageal Adenocarcinoma
Interventions
Cytosponge Procedure, Endoscopic Assessment
Device · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 2 more
Conditions
Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer
Interventions
Nivolumab, Gemcitabine, Cisplatin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
26
States / cities
Tucson, Arizona • Sacramento, California • Littleton, Colorado + 19 more
Conditions
Survivors of Childhood Cancer, Bladder Dysfunction
Interventions
Non-invasive Urodynamic Test (niUDS), Urinary proteomic screen, Dysfunctional Voiding Symptom Score Survey (DVSS)
Diagnostic Test · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 13 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Completed Not applicable Interventional Results available

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT02657486
Conditions
Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma
Interventions
BGJ398
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Muscle-invasive Bladder Urothelial Carcinoma
Interventions
Enfortumab vedotin, Pembrolizumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
Interventions
Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan
Drug · Procedure · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Alamitos, California • Los Angeles, California + 6 more
Conditions
Cutaneous Melanoma
Interventions
Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Surveillance, Ultrasound Imaging, Wide Local Excision
Procedure · Other · Behavioral
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
75 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
181
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 142 more
Enrolling by invitation Not applicable Interventional

TruScore Standalone Clinical Study

NCT06793423
Conditions
Melanoma and Other Malignant Neoplasms of Skin, Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma of the Skin
Interventions
Skin lesion diagnostic device evaluation
Device
Lead sponsor
VeriSkin, Inc.
Industry
Eligibility
22 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Pleasanton, California • Walnut Creek, California • Tampa, Florida + 3 more